Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Paroxetine: current status in psychiatry.

Pae CU, Patkar AA.

Expert Rev Neurother. 2007 Feb;7(2):107-20. Review. Erratum in: Expert Rev Neurother. 2007 Mar;7(3):313-4.

PMID:
17286545
2.

Spotlight on paroxetine in psychiatric disorders in adults.

Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL.

CNS Drugs. 2002;16(6):425-34. Review.

PMID:
12027788
3.
4.

Paroxetine: an update of its use in psychiatric disorders in adults.

Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL.

Drugs. 2002;62(4):655-703. Review. Erratum in: Drugs 2002;62(10):1461.

PMID:
11893234
5.

Paroxetine: safety and tolerability issues.

Marks DM, Park MH, Ham BJ, Han C, Patkar AA, Masand PS, Pae CU.

Expert Opin Drug Saf. 2008 Nov;7(6):783-94. doi: 10.1517/14740330802423168 . Review.

PMID:
18983224
6.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Review. French.

PMID:
18922243
7.

Paroxetine: a review.

Bourin M, Chue P, Guillon Y.

CNS Drug Rev. 2001 Spring;7(1):25-47. Review.

8.

Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review.

Bourin M.

Hum Psychopharmacol. 2003 Apr;18(3):185-90. Review.

PMID:
12672169
9.

Selective serotonin-reuptake inhibitors: an update.

Masand PS, Gupta S.

Harv Rev Psychiatry. 1999 Jul-Aug;7(2):69-84. Review.

PMID:
10471245
10.

Obsessive-compulsive disorder: implications of the efficacy of an SSRI, paroxetine.

Ninan PT.

Psychopharmacol Bull. 2003 Spring;37 Suppl 1:89-96. Review.

PMID:
14566204
11.

Paroxetine.

Tang SW, Helmeste D.

Expert Opin Pharmacother. 2008 Apr;9(5):787-94. doi: 10.1517/14656566.9.5.787 . Review.

PMID:
18345955
12.

Selective serotonin reuptake inhibitors in the treatment of paediatric anxiety disorders: a review.

Murphy TK, Bengtson MA, Tan JY, Carbonell E, Levin GM.

Int Clin Psychopharmacol. 2000 Aug;15 Suppl 2:S47-63. Review.

PMID:
11110019
13.

Where are we going with SSRIs?

Isaac M.

Eur Neuropsychopharmacol. 1999 Jul;9 Suppl 3:S101-6. Review.

PMID:
10523065
14.

Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.

Zohar J, Westenberg HG.

Acta Psychiatr Scand Suppl. 2000;403:39-49. Review.

PMID:
11019934
15.

Potential indications for the selective serotonin reuptake inhibitors.

Boyer WF.

Int Clin Psychopharmacol. 1992 Jun;6 Suppl 5:5-12. Review.

PMID:
1431022
16.

Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders.

Figgitt DP, McClellan KJ.

Drugs. 2000 Oct;60(4):925-54. Review.

PMID:
11085201
17.

Efficacy and tolerability of controlled-release paroxetine.

Golden RN.

Psychopharmacol Bull. 2003 Spring;37 Suppl 1:176-86. Review.

PMID:
14566210
18.

Focus on paroxetine.

Green B.

Curr Med Res Opin. 2003;19(1):13-21. Review.

PMID:
12661775
19.

The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

MacQueen G, Born L, Steiner M.

CNS Drug Rev. 2001 Spring;7(1):1-24. Review.

20.

Antidepressants: update on new agents and indications.

Ables AZ, Baughman OL 3rd.

Am Fam Physician. 2003 Feb 1;67(3):547-54. Review. Erratum in: Am Fam Physician. 2004 Mar 1;69(5):1049. Am Fam Physician. 2003 May 1;67(9):1874.

Items per page

Supplemental Content

Support Center